z-logo
open-access-imgOpen Access
Bicanalicular lacrimal intubation as a primary surgical treatment for nasolacrimal duct obstruction in children
Author(s) -
Raafat Mohyeldeen Abdelrahman Abdallah
Publication year - 2016
Publication title -
journal of egyptian ophthalmological society
Language(s) - English
Resource type - Journals
eISSN - 2314-6648
pISSN - 2090-0686
DOI - 10.4103/2090-0686.192742
Subject(s) - medicine , nasolacrimal duct obstruction , intubation , nasolacrimal duct , surgery , dacryocystorhinostomy
Purpose The purpose of this study was to evaluate the success of bicanalicular lacrimal intubation as a primary treatment in cases of epiphora caused by congenital nasolacrimal duct obstruction in children up to 6 years of age.Patients and methodsA prospective surgical intervention case series study was carried out in the Ophthalmology Department of Minia University Hospital. Forty-six eyes of 43 children with epiphora (dated since birth or shortly after) were enroled in this study. A bicanalicular lacrimal silicon tube was introduced through the nasolacrimal duct to the nose.ResultsIn this study, the primary lacrimal intubation was successful in 40 eyes out of 46 eyes (87%). For children aged 1–2 years, primary intubation was successful in 22 eyes out of 24 (91.6%), and for those aged 2–4 years it was successful in 12 eyes out of 14 (85.7%). On the other hand, for children aged between 4 and 6 years, the procedure was less successful: six eyes out of eight (75%). Improvement of symptoms occurred in two eyes out of four (50%) when the tubes were removed early, and this rate increased to 90.9% in 20 out of 22 eyes when the tubes were retained for up to 3–6 months and to 90% in 18 out of 20 eyes when the tubes were retained for up to 6–12 months.ConclusionBicanalicular lacrimal intubation is a successful treatment for children with nasolacrimal duct obstruction, and the younger the age of the children the higher the success rate

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here